Antidepressants for generalised anxiety disorder (GAD)
- 22 April 2003
- reference entry
- review article
- Published by Wiley
- No. 2,p. CD003592
- https://doi.org/10.1002/14651858.cd003592
Abstract
Pharmacological treatments have been successfully used to treat Generalized Anxiety Disorder (GAD). The mainstay for the pharmacological treatment of GAD in past decades has been the use of benzodiazepine and non benzodiazepine anxiolytics. Data emerging over the last two decades have shown that antidepressants may be equally effective to anxiolytics for treating GAD. The use of antidepressants for treating GAD may be advantageous, due to the fact that GAD presents a high co morbidity ratio with major depressive disorder (62%) and dysthymia (37%). To assess the efficacy and acceptability of antidepressants for treating generalized anxiety disorder. Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Register - CCDANCTR (up to May 2002), Anxiety Neurosis (up to May 2002) and Cochrane Controlled Trials Register (CENTRAL/CCTR) (up to May 2002), MEDLINE (1966 to May 2002), LILACS (1982 to May 2002); reference searching; personal communication; conference abstracts and book chapters on the treatment of generalized anxiety disorder. Randomised controlled trials were included. Exclusion criteria were: non randomised studies; studies which included patients with generalized anxiety disorder and another Axis I co-morbidity. The data from studies were extracted independently by two reviewers and relative risks, weighted mean difference and number needed to treat were estimated. People who died or dropped out were regarded as having had no improvement. Antidepressants (imipramine, venlafaxine and paroxetine) were found to be superior to placebo in treating GAD. The calculated NNT for antidepressants in GAD is 5.15. Dropout rates did not differ between antidepressants. Only one study presented data on imipramine and trazodone. Imipramine was chosen as the reference drug and, therefore, data on trazodone could not be included in the meta analysis. Only one study was conducted among children and adolescents (Rynn 2001). The latter study showed very promising results of sertraline in children and adolescents with GAD, which warrants its replication in larger samples. The available evidence suggests that antidepressants are superior to placebo in treating GAD. There is evidence from one trial suggesting that paroxetine and imipramine have a similar efficacy and tolerability. There is also evidence from placebo-controlled trials suggesting that these drugs are well tolerated by GAD patients. Further trials of antidepressants for GAD will help to demonstrate which antidepressants should be used for which patients.Keywords
This publication has 28 references indexed in Scilit:
- Pattern of Symptom Improvement Following Treatment With Venlafaxine XR in Patients With Generalized Anxiety DisorderThe Journal of Clinical Psychiatry, 2001
- Venlafaxine Extended Release (ER) in the Treatment of Generalised Anxiety DisorderThe British Journal of Psychiatry, 2001
- Paroxetine in the Treatment of Generalized Anxiety DisorderThe Journal of Clinical Psychiatry, 2001
- Efficacy of Venlafaxine Extended-Release Capsules in Nondepressed Outpatients With Generalized Anxiety DisorderJAMA, 2000
- Efficacy of Extended-Release Venlafaxine in Nondepressed Outpatients With Generalized Anxiety DisorderAmerican Journal of Psychiatry, 2000
- Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder.The Journal of Clinical Psychiatry, 1999
- Paroxetine efficacy in the treatment of generalized anxiety disorderActa Psychiatrica Scandinavica, 1997
- Antidepressants for the Treatment of Generalized Anxiety DisorderArchives of General Psychiatry, 1993